img
Susannah Cantrell, Ph.D.

Chief Business Officer

img
Susannah Cantrell, Ph.D.

Chief Business Officer

Dr. Cantrell brings with her more than 20 years of healthcare and biotechnology industry experience spanning global pipeline strategy, sales, operations, marketing and new product commercialization.

Prior to joining Brii Bio, Dr. Cantrell served as Chief Operating Officer and Chief Business Officer at Second Genome, overseeing all aspects of operations across the growing company, including R&D, finance and facilities, among other key functions. Prior to that, she was Executive Vice President and Chief Commercial Officer at Tricida, where she established and built a high-performing U.S.-focused commercial organization. Dr. Cantrell also previously held the role of Vice President and Head of Global Commercial Strategy and Marketing Oncology at Gilead Sciences where she was instrumental in leading and growing the Company’s oncology and inflammation businesses from 2011 to 2019. She also held various senior level and sales and marketing positions early on in her career at global pharmaceutical giants, Genentech/Roche and GlaxoSmithKline.

Dr. Cantrell holds a B.A. in Biology from Westminster College and a Ph.D. in Biochemistry from the University of Missouri-Columbia.

img
Eleanor (Ellee) de Groot, Ph.D.

Chief Technology Officer

img
Eleanor (Ellee) de Groot, Ph.D.

Chief Technology Officer

Dr. de Groot has more than two decades of experience leading a wide range of streamlined global operations across growing biotechnology companies, from early to late stage clinical development and commercial-scale manufacturing. Dr. de Groot held key leadership roles during her career with Alaunos Therapeutics, most recently serving as Executive Vice President of Operations where she oversaw the development of novel cell therapy programs and led clinical manufacturing, quality and process development. In addition, during her extended tenure at Helsinn Therapeutics, Dr. de Groot held multiple roles of increasing responsibility within CMC management where she directed preparations for drug product commercialization, including global regulatory engagement, technology transfers and collaborations with key business partners worldwide.

Dr. de Groot holds both a Ph.D. and Master of Science degree in chemical engineering from Stanford University, a Bachelor of Science degree in chemical engineering from Massachusetts Institute of Technology (MIT) and a Master of Business Administration from Rice University.

img
Zhi Hong, Ph.D.

Executive Director, Chairman of the Board and Chief Executive Officer

img
Zhi Hong, Ph.D.

Executive Director, Chairman of the Board and Chief Executive Officer

Dr. Hong co-founded Brii Bio in 2018 and has served as Chief Executive Officer since the company’s inception. Prior to starting Brii Bio, Dr. Hong was Senior Vice President and Head of GlaxoSmithKline's (GSK) Infectious Diseases Therapy Area Unit. He was widely credited as the key architect of GSK's comeback and success in anti-HIV, anti-HBV and antibiotics medicine discovery and development. Under his leadership, ViiV Healthcare’s (a joint venture between GSK, Pfizer, and Shionogi) HIV business was revitalized with the approval of Tivicay, Triumeq, Cabenuva and Apretude. His leadership also led to the discovery and development of gepotidacin (gram negative antibiotic) and bepirovirsen (anti-HBV) to late stage development.

Dr. Hong is a public health advocate who has helped establish multiple public-private partnerships with the U.S./EU governments (DTRA, BARDA, NIH & IMI) and philanthropic organizations (Gates Foundation & Wellcome Trust). He was the champion of GSK's effort in long-acting HIV treatment and prevention therapies, resulting in the first-of-its kind approval of Cabenuva and Apretude. He helped to create GSK's Institute for Infectious Diseases and Public Health in Beijing, China. Dr. Hong started Ardea Biosciences (later acquired by AstraZeneca). He also held leadership positions at Valeant Pharmaceuticals and Schering-Plough Research Institute (now Merck). Dr. Hong has more than 25 years of experience in drug discovery and development and has brought more than 40 compounds into development, including many that have been approved and launched. He has served as a board member of ViiV Healthcare.

img
Ankang Li, Ph.D., J.D., CFA

Executive Director, Chief Strategy and Financial Officer
Chief Executive Officer of TSB Therapeutics

img
Ankang Li, Ph.D., J.D., CFA

Executive Director, Chief Strategy and Financial Officer
Chief Executive Officer of TSB Therapeutics

Dr. Li is accountable for Brii’s corporate finance and accounting, reporting and control, legal, investor relations, corporate communications, operation excellence and strategy development.

Dr. Li has more than 10 years of experience in investment banking, business development, legal transaction and biomedical research. Before joining Brii Bio, he was the CFO of Terns Biopharmaceuticals to develop and deploy financial and corporate strategies and budget. Prior to Terns, Dr. Li was the Executive Director of Healthcare Investment Banking at Goldman Sachs, responsible for Asia ex-Japan investment banking and led many high-profile IPOs for biotechnology and other healthcare clients. Dr. Li also worked in Merck (known as MSD outside of the U.S. and Canada) Asia Pacific Innovation Hub, overseeing business development and licensing transactions in the region. Before that, Dr. Li worked at both Davis Polk and Ropes & Gray, advising clients on capital markets and M&A transactions. His working career started in the Salk Institute as a postdoctoral biomedical researcher.

Dr. Li received a Juris Doctor degree from the University of Chicago Law School, a Ph.D. degree in Biomedical Sciences from Baylor College of Medicine, a Master of Science degree in Biological Sciences from the National University of Singapore, and a Bachelor of Science degree in Biochemistry from Fudan University. He is also a chartered Financial Analyst (CFA).

img
Rico Liang

General Manager, Greater China

img
Rico Liang

General Manager, Greater China

Mr. Liang leads Brii Biosciences’ business in China, including Medical Affairs, Regulatory Affairs, Government Affairs, Commercialization and Operations.

Mr. Liang has more than 20 years of experience in the pharmaceutical and biotechnology industries with a background that spans medical affairs and commercialization across multiple therapeutic areas. Throughout his decades-long career, he has held high-level positions at several multi-national companies and has worked extensively in the hepatitis space, in particular, acquiring in-depth knowledge and insights of the unmet needs that exist for patients and healthcare providers alike.

Previously, Mr. Liang held the role of Vice President of Scientific and Medical Affairs at Brii Bio, where he oversaw external scientific engagement with KOLs, medical associations and patient communities, and also served as an effective and compelling leader. Prior to joining Brii, he was Executive Director at Gilead China, where he successfully launched eight innovative brands in HBV, HCV and HIV, and built high performing commercial teams to establish strong foundations for long-term business growth. Mr. Liang also worked at notable industry giants such as Amgen, Novartis, Roche, and AbbVie, where he developed a successful record of integrating patient unmet needs and scientific evidence into meaningful product portfolios. Before his career in the drug development industry, Mr. Liang spent five years as a physician at Beijing Fuxing Hospital.

Mr. Liang obtained his Master degree in Marketing from Macquarie University in Australia, and his Bachelor degree in Clinical Medicine is from the Capital University of Medicine Science in China.

img
David Margolis, M.D., MPH

Head of Infectious Diseases Therapy Area

img
David Margolis, M.D., MPH

Head of Infectious Diseases Therapy Area

Dr. Margolis is accountable for Brii’s clinical programs of infectious diseases therapy area in the U.S. and provides strategic input and support for the clinical programs in China.

Prior to joining the company, Dr. Margolis was Medical Director and Senior Medical Director for both GSK and ViiV Healthcare, serving as the lead physician for the clinical development program for the long-acting integrase inhibitor, cabotegravir. Within this role he created and executed the strategic plan for the clinical development of this first long-acting treatment regimen in HIV, CAB+RPV, inclusive of the clinical collaborations with Janssen Pharmaceuticals, IMPAACT and the ACTG, resulting in worldwide regulatory submissions and the first approval and launch of this novel approach to HIV therapy. Dr. Margolis also oversaw the clinical collaboration with the NIH for the evaluation of cabotegravir for the prevention of HIV and has worked across all stages of clinical development from pre-clinical discovery through Phase 3 and post-marketing studies. While at GSK and ViiV, Dr. Margolis maintained a clinical ID practice, serving as an Assistant Consulting Professor in the Infectious Diseases Department of Duke University Medical Center for the prior 8 years, caring for patients with infectious diseases and serving as the lead attending for the ID fellow’s clinic.

Dr. Margolis received his M.D. from Duke University School of Medicine, concurrent with a Masters of Public Health at the University of North Carolina, Chapel Hill and then completed an Internal Medicine residency at University of Colorado Health Science Center and a fellowship in Infectious Diseases at University of California at San Diego in La Jolla, with a research focus on infectious diseases in the immunocompromised host.

img
Karen D. Neuendorff

Chief People Officer and Head of Human Resources

img
Karen D. Neuendorff

Chief People Officer and Head of Human Resources

Ms. Neuendorff brings more than 20 years of experience as a transformational HR leader with a passion for harnessing human capital as a key driver of business.

Before joining Brii Bio, Ms. Neuendorff served as the Senior Vice President of Human Resources at WeDriveU, a division of the premier transportation firm National Express LLC, where she led HR strategy, recruiting and talent management, acting as a trusted advisor to senior leaders and operational talent alike. Prior to her time at WeDriveU, Ms. Neuendorff served as Vice President, Global Human Resources at Nexant for 14 years, where she managed operational functions for the organization to create a unified, value-based culture and brand globally. Throughout her career, she has converted business visions into HR initiatives that improved performance, profitability, growth, and employee engagement on a global scale.

Ms. Neuendorff holds a Bachelor of Arts degree in Psychology from the University of San Francisco. She is also certified as a Senior Professional in Human Resources (SPHR, SHRM-SCP), a Global Professional in Human Resources (GPHR), and a California Professional in Human Resources (PHR-CA).

img
Aleksandar Skuban, M.D.

Head of CNS Diseases Therapy Area

img
Aleksandar Skuban, M.D.

Head of CNS Diseases Therapy Area

Dr. Skuban brings to Brii Bio more than 25 years of global pharmaceutical R&D experience with an extensive medical, scientific and business leadership track record of achievements, including leading more than 30 studies across therapeutic areas from early stage proof of concept through positive regulatory outcomes, with a focus in central nervous system (CNS) diseases. Previously, Dr. Skuban served as SVP of Clinical Development at Better Therapeutics, where he shaped research strategy to enable rapid development of new indications for prescription digital therapeutics. Prior to that, he served as an Executive Medical Director leading clinical development within Alexion’s emerging ophthalmology therapeutic area. At Otsuka Pharmaceuticals, Dr. Skuban’s tenure included roles overseeing various clinical portfolios, notably guiding to FDA approval for Brexpiprazole (REXULTI) for major depressive disorder and schizophrenia.

Dr. Skuban also held a number of clinical development director roles at Merck and Sanofi-Aventis. He earned a M.D. from Semmelweis University of Medicine, Budapest, Hungary and attended the School of Medicine at the University of Novi Sad, Novi Sad, Yugoslavia (Serbia).

img
Coy Stout

Head of Patient Advocacy

img
Coy Stout

Head of Patient Advocacy

Mr. Stout brings with him more than 25 years of experience as a leader in public health and the biopharmaceutical industry, establishing strategic commercial planning and infrastructure to help advance patient access in the U.S. to important medications across a variety of disease areas, especially infectious diseases.

Prior to joining Brii Bio, Mr. Stout served as the Vice President of U.S. Commercial Access and Reimbursement overseeing key federal accounts at Gilead Sciences. He held increasing leadership positions at Gilead during his 17-year tenure, including roles focused on commercial access and reimbursement and worked closely with government affairs and policy teams to inform product planning initiatives. In addition to his expertise in drug coverage, innovative payment models and patient support programs, Mr. Stout has a proven track record of leading access and reimbursement efforts for more than 30 product launches. As a life-long advocate for patient care, he also has experience overseeing teams in community-based settings as a licensed social worker dedicated to supporting people living with HIV/AIDS.

img
Lianhong Xu, Ph.D.

Head of Discovery

img
Lianhong Xu, Ph.D.

Head of Discovery

Dr. Xu had an illustrious career at Gilead Sciences where she was a senior director, a co-inventor of several successful antiviral therapies, and led the discovery efforts in many therapeutic areas against HIV, HCV, HBV, and cancers resulting in numerous clinical candidates. In particular, she was the project leader for the pharmacoenhancer project responsible for the discovery of Tybost® (cobicistat), a component of Stribild® and Genvoya®, and she played a key role in the HCV NS5A project that led to the discovery of ledipasvir, a component of Harvoni®. Harvoni and Genvoya represent two of the most successful pharmaceutical launches and account for multi-billion dollar sales annually.

Dr. Xu holds a B.S. in chemistry from Nankai University (PRC) and a Ph.D. in synthetic organic chemistry from Rice University. She has co-authored more than 30 peer-reviewed scientific publications and holds more than 30 issued patents and applications.

img
Li Yan, M.D., Ph.D.

Chief Medical Officer

img
Li Yan, M.D., Ph.D.

Chief Medical Officer

Dr. Yan is responsible for Brii Bio’s clinical development, regulatory affairs, medical affairs, drug safety, and other related functions. He is accountable for developing and driving the execution of clinical development programs and registrations.

Prior to joining the company, Dr. Yan was Vice President and Head Unit Physician of GSK Oncology, where he oversaw global development of oncology assets focusing on immunotherapy, cancer epigenetics, and cell therapy.

Dr. Yan received his M.D. from the Medical College of Peking University and a Ph.D. from the University of Kansas Medical Center. He is an adjunct professor in Yonsei University.

img
Qing Zhu Ph.D.

Head of China R&D

img
Qing Zhu Ph.D.

Head of China R&D

Prior to joining the company, Dr. Zhu spent 10 years at MedImmune in the United States, where she served as the Director of Infectious Diseases and Vaccines with a particular focus in the fields of antiviral biologics and novel biotherapeutics. At MedImmune, Dr. Zhu led cross-functional matrix teams to progress antibody candidates from preclinical to clinical studies, and contributed to the regulatory submissions (IND/BLA) of several antibody drugs targeting respiratory syncytia virus and influenza.

Earlier in her career, Dr. Zhu held positions of increasing responsibility at Chiron Corporation (later Novartis Vaccines and Diagnostics) developing vaccines and a small molecular inhibitor against the hepatitis C virus.

Dr. Zhu received her Ph.D. in molecular and cell biology from the University of Maryland. She completed her post-doctoral training in the virology program at Fox Chase Cancer Center.

img
Zhi Hong, Ph.D.

Executive Director, Chairman

img
Zhi Hong, Ph.D.

Executive Director, Chairman

Dr. Hong co-founded Brii Bio in 2018 and has served as Chief Executive Officer since the company’s inception. Prior to starting Brii Bio, Dr. Hong was Senior Vice President and Head of GlaxoSmithKline's (GSK) Infectious Diseases Therapy Area Unit. He was widely credited as the key architect of GSK's comeback and success in anti-HIV, anti-HBV and antibiotics medicine discovery and development. Under his leadership, ViiV Healthcare’s (a joint venture between GSK, Pfizer, and Shionogi) HIV business was revitalized with the approval of Tivicay, Triumeq, Cabenuva and Apretude. His leadership also led to the discovery and development of gepotidacin (gram negative antibiotic) and bepirovirsen (anti-HBV) to late stage development.

Dr. Hong is a public health advocate who has helped establish multiple public-private partnerships with the U.S./EU governments (DTRA, BARDA, NIH & IMI) and philanthropic organizations (Gates Foundation & Wellcome Trust). He was the champion of GSK's effort in long-acting HIV treatment and prevention therapies, resulting in the first-of-its kind approval of Cabenuva and Apretude. He helped to create GSK's Institute for Infectious Diseases and Public Health in Beijing, China. Dr. Hong started Ardea Biosciences (later acquired by AstraZeneca). He also held leadership positions at Valeant Pharmaceuticals and Schering-Plough Research Institute (now Merck). Dr. Hong has more than 25 years of experience in drug discovery and development and has brought more than 40 compounds into development, including many that have been approved and launched. He has served as a board member of ViiV Healthcare.

img
Ankang Li, Ph.D., J.D., CFA

Executive Director

img
Ankang Li, Ph.D., J.D., CFA

Executive Director

Dr. Li is accountable for Brii’s corporate finance and accounting, reporting and control, legal, investor relations, corporate communications, operation excellence and strategy development.

Dr. Li has more than 10 years of experience in investment banking, business development, legal transaction and biomedical research. Before joining Brii Bio, he was the CFO of Terns Biopharmaceuticals to develop and deploy financial and corporate strategies and budget. Prior to Terns, Dr. Li was the Executive Director of Healthcare Investment Banking at Goldman Sachs, responsible for Asia ex-Japan investment banking and led many high-profile IPOs for biotechnology and other healthcare clients. Dr. Li also worked in Merck (known as MSD outside of the U.S. and Canada) Asia Pacific Innovation Hub, overseeing business development and licensing transactions in the region. Before that, Dr. Li worked at both Davis Polk and Ropes & Gray, advising clients on capital markets and M&A transactions. His working career started in the Salk Institute as a postdoctoral biomedical researcher.

Dr. Li received a Juris Doctor degree from the University of Chicago Law School, a Ph.D. degree in Biomedical Sciences from Baylor College of Medicine, a Master of Science degree in Biological Sciences from the National University of Singapore, and a Bachelor of Science degree in Biochemistry from Fudan University. He is also a chartered Financial Analyst (CFA).

img
Mr. Robert Taylor Nelsen

Non-executive Director

img
Mr. Robert Taylor Nelsen

Non-executive Director

Mr. Robert Taylor Nelsen was appointed as a Director on June 22, 2018 and re-designated as a non-executive Director on March 24, 2021. Since November 2018, February 2019 and February 2019, he has been serving as a director of Brii HK, Brii Shanghai and Brii Beijing, respectively.

Since 1994, Mr. Nelsen has been serving as a co-founder and managing director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, and he has played a significant role in the early sourcing, financing, and development of more than 30 biopharmaceutical companies. In addition, Mr. Nelsen currently holds directorships in multiple biopharmaceutical companies listed on the NASDAQ stock exchange or the Stock Exchange. As a board member, Mr. Nelsen would generally attend board meetings to provide guidance to company strategy and discuss pertinent issues such as fundraising, recruiting, R&D and status of clinical programs. Mr. Nelsen also previously served as a trustee of Fred Hutchinson Cancer Research Center.

Mr. Nelsen obtained his Bachelor of Science with majors in Economics and Biology from the University of Puget Sound in the United States in June 1985 and a Master of Business Administration from the University of Chicago in the United States in June 1987.

img
Dr. Martin J. Murphy Jr.

Independent Non-executive Director

img
Dr. Martin J. Murphy Jr.

Independent Non-executive Director

Dr. Murphy has been serving as the chairman and the chief executive officer of AlphaMed Consulting, Inc., a biomedical consulting company since March 2003. He provides executive consultation on cancer drug development, clinical trial design, key thought leader identification and strategic analysis of big data and artificial intelligence to both corporate executives as well as cancer drug developers.

Dr. Murphy was the founding chief executive officer of CEO Roundtable on Cancer, a non-profit organization that works to develop and implement initiatives that reduce the risk of cancer, from August 2000 to January 2020. He received the Charles A. Sanders Life Sciences Award presented by Life Sciences Consortium and CEO Roundtable on Cancer in November 2019. Dr. Murphy has been the Emeritus Director of the CEO Roundtable on Cancer since January 2021. He has also been a fellow of the American Society of Clinical Oncology since 2013.

Dr. Murphy was awarded a Master of Science in Biology from New York University in the United States in February 1967, a Ph.D in Biology from New York University in the United States in June 1969 and a Doctor of Medical Science (honoris causa) from Queen’s University of Belfast in the United Kingdom in July 2009.

img
Ms. Grace Hui Tang

Independent Non-executive Director

img
Ms. Grace Hui Tang

Independent Non-executive Director

Ms. Grace Hui Tang, has been serving as a director and member of audit committee of Textainer Group Holdings Limited, (stock code: TGH) since July 2020. She has been serving as a professor and interviewer of Peking University’s Guanghua School of Management, and she is responsible for teaching graduate accounting program and interviewing MBA candidates since September 2018. Ms. Tang has held several positions in China, Hong Kong and U.S. Silicon Valley offices in PricewaterhouseCoopers, an accounting firm, from March 1990 to June 2020. Her last position therein was partner in the assurance department in China office and she was responsible for overseeing audit work.

Ms. Tang obtained her Bachelor of Science with majors in Accounting from the University of Utah in the United States in June 1982 and a Master of Business from Utah State University in the United States in June 1984. Ms. Tang has been a certified public accountant of the California Board of Accountancy of the United States since December 1993. She has been a certified public accountant of the Hong Kong Institute of Certified Public Accountants since July 1995. She has been a fellow of the Hong Kong Institute of Certified Public Accountants since March 2003.

img
Mr. Yiu Wa Alec Tsui

Independent Non-executive Director

img
Mr. Yiu Wa Alec Tsui

Independent Non-executive Director

Mr. Yiu Wa Alec Tsui has over 40 years of experience in finance and administration, corporate and strategic planning, information technology and human resources management.

Mr. Tsui has been an independent non-executive director of a number of companies listed on the Stock Exchange, namely, COSCO Shipping International (Hong Kong) Co., Ltd. (stock code: 517) since February 2004, Pacific Online Limited (stock code: 543) since November 2007 and Hua Medicine (stock code: 2552) since September 2018. He has also been serving as the independent director of a number of companies listed on NASDAQ Stock Exchange in the United States, namely, ATA Creativity Global (stock code: AACG) since January 2008 and Melco Resorts & Entertainment Limited (stock code: MLCO) since December 2006. Since August 2000, he has also been an independent non-executive director of Industrial & Commercial Bank of China (Asia) Limited (stock code: 349) and was delisted with effect from December 21, 2010. In addition, Mr. Tsui has been serving as a director to WAG Worldsec Management Consultancy Limited, a consulting company, and he is responsible for setting the strategic direction of the company and the day-to-day management of the company since April 2006. Mr. Tsui also served as independent non-executive directors in various other Hong Kong listed companies previously.

Mr. Tsui was admitted as a member of the Hong Kong Securities and Investment Institute in November 1998 and became the senior fellow of the Hong Kong Securities and Investment Institute in September 2014.

Mr. Tsui obtained his Bachelor of Science in Industrial Engineering from the University of Tennessee in the United States in June 1975 and a Master of Engineering from the University of Tennessee in the United States in August 1976. He also completed the Program for Senior Managers in Government at the John F. Kennedy School of Government at Harvard University in the United States in August 1993.

img
Mr. Gregg Huber Alton

Independent Non-executive Director

img
Mr. Gregg Huber Alton

Independent Non-executive Director

Mr. Gregg Huber Alton has been serving as a director and member of the audit committee of Novavax, Inc., (stock code: NVAX) since November 2020 and December 2020, respectively. He has been serving as a director, the chair of the corporate governance and nominating committee as well as the audit committee, and member of the compensation committee of Corcept Therapeutics Incorporated, (stock code: CORT) since March 2020. Further, Mr. Alton has been serving as a director, member of the audit committee and the chair of the nominating and corporate governance committee of Enochian Biosciences Inc., a pharmaceuticals company listed on NASDAQ Stock Exchange (stock code: ENOB) since December 2019.

Mr. Alton held several positions in Gilead Sciences, Inc., a biopharmaceutical company listed on NASDAQ Stock Exchange in the United States (stock code: GILD) from October 1999 to January 2020, including general counsel, chief patent officer, interim chief executive officer and senior advisor of Gilead Sciences, Inc., and he was responsible for the company’s government affairs, public affairs, patient outreach and engagement initiatives, and led the company’s international commercial operations and corporate affairs groups. Mr. Alton was an associate at Cooley Godward, LLP, a law firm, between November 1993 to December 1996, and June 1998 to October 1999. He was an associate attorney at Mintz Levin P.C., a law firm, from January 1997 to May 1998.

Mr. Alton obtained his Bachelor of Arts with a major in legal studies from the University of California in Berkeley, the United States in May 1989, and a Doctor of Jurisprudence from The Leland Stanford Junior University in the United States in June 1993. Mr. Alton was also admitted as an attorney and counselor at law by the supreme court of the state of California between June 1994 and July 2019.

img
Taiyin Yang, Ph.D.

Independent Non-executive Director

img
Taiyin Yang, Ph.D.

Independent Non-executive Director

Dr. Yang is the former Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences. She directed operations of process, device and formulation development, manufacturing, packaging, analytical operations, laboratory information systems and data science, quality assurance, regulatory affairs, CMC program management, product distribution, supply chain management and site operations. Under her leadership, Gilead developed the world's first HIV single tablet regimen and advanced numerous compounds from early-stage development to market, reaching millions of people around the world. Prior to joining Gilead in 1993, Dr. Yang worked at Syntex Corporation for more than a decade, where she contributed to the development and commercialization of more than 10 medicines.

In 2022, Dr. Yang was elected a member of the National Academy of Engineering. She is a member of the Expert Scientific Advisory Committee of Medicines for Malaria Venture and the scientific advisory board of Sionna Therapeutics. Dr. Yang also serves on the board of directors of Kodiak Sciences and Kronos Bio.

Dr. Yang holds a Ph.D. in organic chemistry from the University of Southern California and a Bachelor of Science degree in chemistry from National Taiwan University.

img
John Maraganore, Ph.D.

Investor and Strategic Advisor

img
John Maraganore, Ph.D.

Investor and Strategic Advisor

CEO of Alnylam Pharmaceuticals 

John Maraganore, Ph.D., has served as CEO and Director of Alnylam since 2002. Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology and cardiovascular, inflammatory, and metabolic diseases. Dr. Maraganore was previously Vice President, Strategic Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology from the University of Chicago. He is the Chair of the Board for Agios Pharmaceuticals. Dr. Maraganore is Chair of the Biotechnology Industry Organization (BIO) Board and is a member of the BIO Executive Committee.

img
David D. Ho, M.D.

Scientific and Strategic Advisor

img
David D. Ho, M.D.

Scientific and Strategic Advisor

Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center

David D. Ho, M.D., is the founding Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center. He is also the Irene Diamond Professor at The Rockefeller University.

Dr. Ho received his degrees from California Institute of Technology (1974) and Harvard Medical School (1978). Subsequently, he did his clinical training in internal medicine and infectious diseases at Cedars-Sinai Medical Center/UCLA School of Medicine (1978-1982) and Massachusetts General Hospital/Harvard Medical School (1982-1985), respectively.

Dr. Ho has been at the forefront of AIDS research for 36 years, publishing over 400 papers. Beginning in 1994, his work unveiled the dynamic nature of HIV replication in vivo and significantly contributed to our understanding of the disease. This knowledge led Dr. Ho to champion combination antiretroviral therapy, which resulted in dramatically improved control of HIV in patients.

Dr. Ho’s research team devotes considerable efforts to developing HIV vaccines, as well as antibody-based strategies and long-acting antiretroviral drugs to prevent the spread of the AIDS epidemic.

Dr. Ho has received numerous honors and awards. He is the recipient of 13 honorary doctorates and accolades including the Ernst Jung Prize in Medicine, Mayor’s Award (New York City) for Excellence in Science & Technology, the Squibb Award, and the Hoechst Marion Roussel Award. Dr. Ho has been elected as a member of the American Academy of Arts and Sciences, Academia Sinica (Republic of China), Chinese Academy of Engineering, and the U.S. National Academy of Medicine. He was also inducted into the California Hall of Fame. Recently, Dr. Ho was recognized by the Kingdom of Thailand with the Prince Mahidol Award in Medicine, and given the Distinguished Alumni Award by CalTech.

Dr. Ho was a member of the Board of Overseers of Harvard University and a board member of the MIT Corporation. He is currently a member of the board of trustees of the California Institute of Technology.

Dr. Ho was named Time Magazine’s Man of the Year in 1996, and in 2001 received the Presidential Citizens Medal from United States President Bill Clinton.

img
Thomas O. Daniel, M.D.

Scientific and Strategic Advisor

img
Thomas O. Daniel, M.D.

Scientific and Strategic Advisor

Former President of Global Research and Early Development at Celgene Corporation

Thomas Daniel, M.D., was President, Global Research and Early Development at Celgene Corporation over the last decade as the company emerged as a leader in defining new mechanisms for drug action, established industry leading collaborative networks, and advanced and commercialized innovative medicines in oncology and inflammatory diseases. Dr. Daniel previously served as Chief Scientific Officer and Director of AmbRx, as Vice President of Research at Amgen, and as Senior Vice President of Discovery Research at Immunex Corporation.

Dr. Daniel is currently chairman at Vividion Therapeutics, a director at VIR Biotechnology, Magenta Therapeutics, ImmunsanT and Zafgen. He is a trustee of Reed College, and serves on the board of the Alliance for Lupus Research, on the Biomedical Science Advisory Board of Vanderbilt University Medical Center, and is a senior advisor to BlackThorn Therapeutics. A nephrologist and former academic investigator, Dr. Daniel was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt. He earned his medical degree from the University of Texas, Southwestern, trained in molecular genetics at UTSW, and completed a medical residency at Massachusetts General Hospital.

img
Chen Dong, Ph.D.

Scientific and Strategic Advisor

img
Chen Dong, Ph.D.

Scientific and Strategic Advisor

Professor at Institute for Immunology at Tsinghua University and Shanghai Jiao Tong University School of Medicine

Chen Dong, Ph.D., is a professor at the Institute for Immunology at Tsinghua University and Shanghai Jiao Tong University School of Medicine. Dr. Dong served as a Professor of Immunology and the Director of the Center for Inflammation and Cancer at the University of Texas MD Anderson Cancer Center before his move to Tsinghua University. Dr. Dong’s research focuses on understanding the molecular mechanisms that regulate immune and inflammatory responses, informing the understanding and treatment of autoimmunity and allergy disorders, as well as cancer. The work from Dr. Dong’s group has led to the discoveries of Th17 and T follicular helper (Tfh) cell subsets in the immune system and elucidation of their biological and pathological functions.

Dr. Dong has over 200 publications and was rated a “highly cited researcher” from 2014 to 2017. The honors he has received include the 2009 American Association of Immunologists BD Bioscience Investigator Award and his election as a Fellow of the American Association for the Advancement of Science in 2011.

img
Zhijian ‘James’ Chen, Ph.D.

Strategic and Scientific Advisor

img
Zhijian ‘James’ Chen, Ph.D.

Strategic and Scientific Advisor

Investigator of Howard Hughes Medical Institute

Professor in the Department of Molecular Biology at the University of Texas Southwestern Medical Center at Dallas

Director of Inflammation Research Center and George L. MacGregor Distinguished Chair in Biomedical Science at UT Southwestern

Zhijian 'James' Chen, Ph. D., is a distinguished scientist, academician and professor in the fields of immunology, inflammation research and biomedical science.

Prior to establishing his academic research laboratory, Chen was a senior scientist at ProScript Inc. where he helped discover the proteasome inhibitor VELCADE, a medicine used for the treatment of multiple myeloma. After joining UT Southwestern in 1997, Chen discovered the regulatory role of ubiquitination in protein kinase activation in the NF-kB and MAP kinase pathways. In addition, he discovered the Mitochondrial Antiviral Signaling (MAVS) protein that reveals a new role of mitochondria in immunity. More recently, Chen discovered cyclic GMP-AMP synthase (cGAS) as a cytosolic DNA sensor and a new cyclic di-nucleotide signaling pathway that mediate innate immune responses in animal cells. For his work, Chen has received numerous honors including the National Academy of Science Award in Molecular Biology (2012), the American Society of Biochemistry and Molecular Biology (ASBMB) Merck Award (2015), the Lurie Prize in Biomedical Sciences from the Foundation of NIH (2018), the Breakthrough Prize in Life Sciences (2019), and the Switzer Prize (2019). Chen is a member of the National Academy of Sciences.

img
Clay B. Thorp

Strategic Advisor

img
Clay B. Thorp

Strategic Advisor

General Partner at Hatteras Venture Partners

Clay B. Thorp is an entrepreneur turned venture capitalist. Since 1995, he has co-founded eight companies in the life science arena and co-founded Hatteras Venture Partners in 2000. Since co-founding Hatteras, Mr. Thorp has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $450 million across five venture funds. He has led investments in a range of life science companies, including biopharmaceuticals, medical devices, diagnostics, and research informatics.

Mr. Thorp began his career in 1995 when he co-founded Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA, and proteins. Shortly thereafter, he co-founded Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon’s sale to Karo Bio for $106.7 million in May of 2000.

Mr. Thorp has led investments and numerous strategic transaction processes in a variety of portfolio companies, including G1 Therapeutics, Clearside Biomedical, Lysosomal Therapeutics, Asthmatx, PhaseBio Pharmaceuticals, ArtusLabs, Embrella, and Synthematix.

Mr. Thorp currently serves as Executive Chairman of PhaseBio Pharmaceuticals and Chairman of GeneCentric Diagnostics. He is also on the boards of Clearside Biomedical (NASDAQ: CLSD), Rodin Therapeutics, Lysosomal Therapeutics, StrideBio, and Orig3n. He serves on the Chancellor’s Philanthropic Committee and the Board of Visitors of the Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill, and on the board of the NC School of Science and Mathematics Foundation.

Mr. Thorp holds a Masters of Public Policy from Harvard University and a B.A. in mathematics and art history from the University of North Carolina at Chapel Hill.